Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

4 items

Immunohistochemical evaluation, where indicated, to assess line of differentiation for classification

Funded Biomarker Disease Site: Soft Tissue

Biomarker:

Testing Method:Immunohistochemistry (IHC)

Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, The Ottawa Hospital

Molecular interrogation, where indicated, for classification, prognostic and/or therapeutic purposes.

Funded Biomarker Disease Site: Soft Tissue

Biomarker: Refer to 2023 Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone

Testing Method:Sequencing

Testing Site: Mount Sinai Hospital, The Ottawa Hospital

Reflex testing on newly diagnosed CD117 (cKIT) positive Gastrointestinal Stromal Tumours

Funded Biomarker Disease Site: Soft Tissue

Biomarker: BRAF, KIT, PDGFRA (Optional 23/24 - SDH, NTRK (fusion))

Testing Method:Sequencing

Testing Site: Hamilton Health Sciences, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, University Health Network

Review of tumour by a subspecialist Pathologist for classification

Funded Biomarker Disease Site: Soft Tissue

Biomarker:

Testing Method:

Testing Site: Hamilton Health Sciences, Mount Sinai Hospital, The Ottawa Hospital